1932

Abstract

Malaria still kills some 0.5–2.5 million people per year in the tropics. Resistance to the cheap, most commonly used antimalarials continues to spread alarmingly and could outpace drug development. The artemisinin derivatives have had an important clinical impact both on the treatment of resistant falciparum malaria and on the incidence of disease in low-transmission areas. A few promising new antimalarials are being tested clinically but there is an imperative need for cheap, well-tolerated drugs that can be used in short courses, and for strategies to delay the onset of drug resistance. Bed nets have been shown to reduce the incidence of severe malaria in many areas but an effective vaccine is urgently needed.

Loading

Article metrics loading...

/content/journals/10.1146/annurev.med.50.1.179
1999-02-01
2024-06-17
Loading full text...

Full text loading...

/content/journals/10.1146/annurev.med.50.1.179
Loading
/content/journals/10.1146/annurev.med.50.1.179
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error